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Neuroendocrine (NE) cells are defined as ar-
gentaffin and argyrophil cells that produce peptides
or amines. They belong to the diffuse neuroen-
docrine system (DNES) and were previously known
as amino-precursor-uptake-decarboxylation
(APUD) cells. The neuroendocrine system of the
normal gastrointestinal tract might regulate prolif-
eration and growth of epithelial and mesenchymal
cells and probably function in sensation of hunger
during fasting and food-intake [1]. Chromogranin
A (CGA), a specific matrix component of endocrine
granules, participates in vesicle aggregation, granu-
logenesis, and hormone secretion and serves as a
precursor for bioactive peptides (prohormone func-
tion) in endocrine and NE cells [2–4]. CGA is stored
in secretory granules of NE cells and is regarded as a
general endocrine marker [5–7]. The presence of
NE cells in carcinomas of the gastrointestinal tract is
well documented but their role remains speculative
[8–21]. In a number of immunohistochemical stud-
ies a prognostic relevance of NE cells in adenocarci-
nomas, mostly colorectal adenocarcinomas, has
been reported, however, several other studies failed
to demonstrate a relation between NE differentia-
tion and biological behavior of colorectal adenocar-
cinomas [9–11,14–22]. Reports on the prevalence
and prognostic significance of NE cells in adenocar-
cinomas of the esophagus and its precursor lesion,
the Barrett’s mucosa, have been scarce. Hamilton et
al. [23] did not find a significant correlation be-
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We estimated the prevalence and prognostic significance of neuroendocrine (NE) cells
in a series of 208 resection specimens containing gastroesophageal junction (GEJ) ade-
nocarcinomas, with 56 specimens containing Barrett’s mucosa. Immunohistochemi-
cally, chromogranin A (CGA) was positive in 49% (102/208) of GEJ adenocarcinomas
and in 68% (38/56) of Barrett’s mucosas. CGA in GEJ tumors correlated with pTNM
stage. CGA in Barrett correlated with pTNM stage and tumor grade of the adjacent car-
cinoma. Patients with CGA in Barrett had better survival than patients without CGA
in Barrett, with 5-year survival percentages of 56% and 9%, respectively. In multi-
variate analysis, CGA in Barrett was an independent prognostic factor for survival af-
ter surgery. Therefore CGA in Barrett adjacent to GEJ adenocarcinoma might be help-
ful in the assessment of patient outcome. Int J Surg Pathol 12(2):117–125, 2004
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tween the presence of chromogranin A (CGA) im-
munoreactive tumor cells and survival in patients
with esophageal adenocarcinoma. We analyzed the
presence of NE cells in 208 resection specimens with
adenocarcinoma of the gastroesophageal junction
(GEJ), i.e., gastric cardia or distal esophagus, and
premalignant Barrett’s mucosa and correlated im-
munostaining with tumor characteristics and pa-
tient survival in order to evaluate the possible ap-
plication of NE cells as prognostic marker. 
Materials and Methods
Tissues and Patients 
Two hundred and eight patients (176 men; 32
women) with GEJ adenocarcinoma who under-
went transhiatal resection of the tumor with
restoration of continuity of the gastrointestinal tract
by a gastric tube with cervical anastomosis were in-
cluded in this study. Patients were operated on be-
tween April 1987 and April 2002 at the Department
of Surgery, Erasmus MC, Rotterdam. A standard
dissection of the perigastric, left gastric, and celiac
nodes was performed. Macroscopic tumor clearance
was aimed at in all cases but no extended lymph
node dissection was done. Seventeen patients re-
ceived neoadjuvant chemotherapy and 2 patients
received neoadjuvant chemoradiation. Patients’
mean age was 63.6 years (range 39–84 years) at the
time of diagnosis. All patients were followed up un-
til April 2003 or until death if earlier. All 208 pathol-
ogy records were reviewed. Barrett’s mucosa was
diagnosed by the GI-pathologist and was defined as
the presence of intestinal-type epithelium with
Goblet cells in the tubular esophagus [24]. 
In 73 patients Barrett’s mucosa had been sampled
before development of adenocarcinoma. Barrett’s
mucosa adjacent to tumor could be obtained in 56
of these 73 resection specimens, whereas in 17 re-
section specimens the Barrett’s mucosa could not be
detected. Barrett’s mucosa showed no signs of dys-
plasia in 22, low-grade dysplasia in 22, and high-
grade dysplasia in 12 resection specimens. A carci-
noma was considered to arise from the distal
esophagus when premalignant Barrett’s mucosa
was present and/or the epicenter of the mass was
located in the tubular esophagus extending from
the tracheal bifurcation to the gastroesophageal
junction including the intraabdominal esophagus,
according to the TNM classification (International
Classification of Diseases for Oncology C15.5). The
tumor was considered to be cardiac when the epi-
center was immediately below the gastroesophageal
junction, extending approximately 2 cm down-
ward. The tumor was classified as a junction carci-
noma when the epicenter was just at the GEJ, with-
out predominance for distal esophagus or gastric
cardia and no Barrett’s mucosa was present. Tumors
arising from the fundus or corpus of the stomach
and infiltrating the gastric cardia or distal esophagus
were excluded. Of the adenocarcinomas in our pa-
tient group, 112 arose from the distal esophagus
and 73 arose from the cardia. The exact location of
23 GEJ adenocarcinomas could not be specified as
either distal esophagus or gastric cardia and these
were classified as junction carcinomas. 
Immunohistochemical Analyses 
From formalin-fixed, paraffin-embedded tissue
blocks of the primary tumor, 4-µm-thick sections
were mounted on 3-aminopropyl-triethoxysilane
(APES)-coated glass slides. For immunostaining a
monoclonal antibody against CGA (Hybritech, San
Diego, USA, at a dilution of 1:1,250) was used.
Staining was carried out by a standard avidin biotin
immunoperoxidase technique, using a commercially
available kit (Labvision, Fremont, USA). Deparaf-
finized sections were treated with methanol con-
taining 3% H2O2 for 20 minutes. After washing with
phosphate-buffered saline (PBS), blocking serum
was applied for 5 minutes. Then, primary CGA anti-
bodies were allowed to react at room temperature
for 1 hour. After washing in PBS, biotin-conjugated
secondary antibody was applied for 10 minutes fol-
lowed by peroxidase-marked streptavidin. After
rinsing in PBS, peroxidase was visualized by di-
aminobenzidine hydrochloride (Fluka, Neu-Ulm,
Germany) with 0.03% H2O2 solution for 10 min-
utes. The slides were counterstained with Mayer’s
Hematoxylin and dehydrated in alcohol before
mounting. Expression of CGA was evaluated by
high-power microscopic examination (400×) of the
entire tissue section. As negative controls normal
mouse immunoglobulins and normal rabbit serum
were applied on duplicate sections. Positive controls
using normal colonic epithelium were also run with
each batch, in addition to using noninvolved normal
gastric mucosa in the resection specimens, if present,
as an internal positive control. Scoring of cytoplas-
mic CGA expression in adenocarcinomas was based
on the percentage of positive cells: >20% of cells
with cytoplasmic staining (2+), 1–20% of cells with
cytoplasmic staining (1+), no cells staining (0). 
Statistical Analysis
Correlations between CGA immunoreactivity
and patient and tumor characteristics were assessed
by t test and (a trend version of ) χ2 test. Survival
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rates were calculated according to the Kaplan-Meier
method and differences in survival were assessed by
using the log rank test; p<0.05 was considered sta-
tistically significant. The Cox regression model was
used to analyze the independent prognostic value of
CGA expression after correction for possible con-
founding factors. 
Results
CGA expression was detected in 102/208 (49%)
adenocarcinomas of the GEJ (Table 1). The CGA-
positive cells mostly presented diffusely scattered
throughout the tissue or multifocally located in
small nests, with just 8 tumors having >20% (2+)
CGA-positive cells (Fig. 1). For statistical compari-
son we hence combined the groups with 1+ and 2+
staining. Negative controls did not show staining,
and positive controls were positive. In 56 of the 208
resection specimens Barrett’s mucosa adjacent to
adenocarcinoma was detected. Positive staining for
CGA was seen in 38/56 cases (68%). CGA im-
munoreactivity was absent in 18/38 (47%) tumors
with CGA-positive Barrett’s mucosa (Table 1). There
was no correlation between CGA immunoreactivity
in Barrett’s mucosas and CGA immunoreactivity in
adenocarcinomas (p=0.57). In the patients with
Barrett’s mucosa adjacent to tumor, there was no
correlation between CGA immunoreactivity in the
Barrett and presence or degree of dysplasia (p=0.97
and p=0.65, respectively). 
CGA-positive staining in GEJ tumors correlated
with a more favorable pTNM stage (p=0.04, Table
2). CGA-positive staining in Barrett’s mucosas cor-
related with a more favorable pTNM stage and tu-
mor grade (p=0.005 and p=0.024, respectively,
Table 2). No difference in survival between patients
with CGA-positive and CGA-negative adenocarci-
nomas was found (p=0.69, Fig. 2). Five-year sur-
vival percentages were 30% and 28%, respectively.
However, patients with CGA-positive cells in Bar-
rett’s mucosa adjacent to the tumor had a better sur-
vival than patients without CGA-positive cells in
Barrett’s mucosa (p=0.0015, Fig. 3). Five-year sur-
vival percentages were 56% and 9% for patients
with and without CGA expression in Barrett, re-
spectively. Univariate analysis to identify prognostic
variables in the total group showed pTNM stage, tu-
mor grade, and radicality of resection to be prog-
nostic factors for survival (p=<0.001, p=0.012, and
p=<0.001, respectively). In multivariate Cox regres-
sion analysis only pTNM-stage and radicality of re-
section turned out to be independent prognostic
factors for survival in the total patient group
(p=0.003 and p=0.006, Table 3A). However, in the
group of patients with Barrett’s mucosa, univariate
analysis showed age, radicality of resection, and
CGA immunoreactivity in the Barrett’s mucosa to
be prognostic for survival (p=0.035, p=0.008, and
p=0.003, respectively, Table 3B), which was sub-
stantiated by multivariate analysis (p=0.03,
p=0.037, and p=0.003, respectively, Table 3B).
Discussion
Our study, which showed that the presence of NE
cells in GEJ tumors did not correlate with 5-year
survival rate, is in concordance with the results re-
ported by Hamilton et al. [23]. They investigated
the expression of CGA in 52 patients with adeno-
carcinomas of the esophagus and did not find a cor-
relation with survival [23]. We also confirm their
findings of CGA-positive Barrett’s mucosas with ad-
jacent CGA-negative tumors (namely, in 38% of
their tumors and in 47% of our tumors). Obviously
neuroendocrine differentiation commonly disap-
pears in invasive adenocarcinomas. We likewise ob-
served NE cells more often in Barrett’s mucosa
without dysplasia or with low-grade dysplasia than
in high-grade dysplastic Barrett’s mucosas, although
this difference lacked statistical significance. Hamil-
ton et al. found expression of CGA in 62% (21/34)
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Table 1. CGA Expression in Adenocarcinomas of the GEJ and Barrett’s Mucosa
Barrett’s Mucosa
Non-Barrett CGA Positive CGA Negative Total
Adenocarcinomas
CGA positive 074 20 08 102
CGA negative 078 18 10 106
Total 152 38 18 208
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of the Barrett’s mucosas, as compared to our finding
of 68% (38/56). In our study, patients with CGA-
positive Barrett’s mucosa had a better survival rate
than patients with CGA-negative Barrett’s mucosa.
Our study differs from the study of Hamilton et al.
in several ways. The monoclonal CGA antibody we
used differs from the antibody used by Hamilton et
al. Our study encompasses 208 patients versus 52
patients in the study of Hamilton et al. Finally, their
population contained 37 of 52 patients who under-
went preoperative therapy, compared to 19 of our
208 patients, and this might influence CGA stain-
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Fig. 1. A. CGA immunoreactivity in normal gastric epithelium. B. CGA-negative adenocarcinoma. C. Scat-
ters of individual tumor cells show CGA staining (1+) within a well-differentiated adenocarcinoma. D. Ade-
nocarcinoma shows apparent cytoplasmic CGA staining in >20% (2+) of tumor cells. E. CGA-negative 
Barrett’s epithelium adjacent to adenocarcinoma. F. CGA-positive cells in Barrett’s epithelium most promi-
nently located in the basal layer of the epithelium. 
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ing. However, when the 19 patients who received
preoperative therapy were left out from the analy-
ses, our results did not change. Moreover, Shia et al.
[25] suggested that the increased endocrine differ-
entiation shown in rectal adenocarcinomas treated
by chemo(radio)therapy could be related to ther-
apy-induced cytotoxity, which is in contrast to the
lower percentage of CGA-positive patients, al-
though there was a higher percentage of pretreated
patients in the study of Hamilton et al. as compared
to our study. Since adenocarcinomas of the distal
esophagus and the gastric cardia are regarded as one
clinical entity by some authors [26,27], we investi-
gated the expression of NE markers in adenocarci-
nomas of the GEJ, whereas in the study of Hamilton
et al., only esophageal adenocarcinomas were in-
cluded. Because the prevalence of NE differentia-
tion in our series was about the same in esophageal
and cardia adenocarcinomas, the different results
cannot be ascribed to the fact that in our study car-
dia adenocarcinomas were included. 
Several studies concerning colorectal carcinomas
showed that the presence of CGA-positive cells does
not influence prognosis [14–19], whereas other
studies indicate that CGA expression in tumor cells
might distinguish a subgroup of colorectal carcino-
mas with poorer prognosis [10–12,21]. Swatek and
Chibowski [13], using immunostaining for CGA, re-
ported that endocrine cells were significantly more
frequent in less advanced and better differentiated
colorectal carcinomas. Two other studies showed a
significantly better survival in patients with NE ex-
pression in pancreatic cancer and nonsmall cell lung
cancer [28,29]. 
In the current study we demonstrated that CGA
expression in Barrett’s mucosa adjacent to the tumor
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Table 2. Clinicopathological Characteristics of 208 Patients with GEJ Adenocarcinomas 
and Barrett’s Mucosa Adjacent to Tumor (If Present, 56 of 208 Patients)
Chromogranin A in Tumor Chromogranin A in Barrett’s Mucosa
Gender
Male 85 (83) 91 (86) 176 (85) 30 (79) 17 (94) 47 (84)
Female 17 (17) 15 (14) 32 (15) 0.76 8 (21) 1 (6) 9 (16) 0.25
Mean age, years ± SD 63.6 ± 10.1 63.6 ± 9.2 63.6 ± 9.7 0.94† 64.8 ± 10.0 64.2 ± 10.9 64.6 ± 10.2 0.99†
pTNM-stage
I 11 (11) 5 (5) 16 (8) 10 (26) — 10 (18)
II 34 (33) 33 (31) 67 (32) 16 (42) 4 (22) 20 (36)
III 48 (47) 50 (47) 98 (47) 7 (18) 11 (61) 18 (32)
IV 9 (9) 18 (17) 27 (13) 0.04 5 (13) 3 (17) 8 (14) 0.005
Tumor grade
Well 5 (5) 4 (4) 9 (4) 4 (11) — 4 (7)
Moderate 47 (46) 41 (39) 88 (42) 18 (47) 5 (28) 23 (41)
Poor 50 (49) 61 (58) 111 (53) 0.23 16 (42) 13 (72) 29 (52) 0.024
Radicality
R0 71 (70) 76 (72) 147 (71) 29 (76) 11 (61) 40 (71)
R1, R2 31 (30) 30 (28) 61 (29) 0.86 9 (24) 7 (39) 16 (29) 0.39
Tumor location
Esophagus 58 (57) 54 (51) 112 (54) 38 18 56
GEJ 8 (8) 15 (14) 23 (11) — — —
Cardia 36 (35) 37 (35) 73 (35) 0.67 — — — —
Dysplasia
Absent 15 (40) 7 (39) 22 (39)
Low grade 16 (42) 6 (33) 22 (39)
High grade 7 (18) 5 (28) 12 (21) 0.65
*P value by (a trend version of) χ2 test; †P value by t test.
Number of
Tumors
Positive
(%)
Number of
Tumors
Negative
(%)
Total
Number of
Tumors
(%) p Value* p Value*
Number of
Barrett’s
Positive
(%)
Number of
Barrett’s
Negative
(%)
Total
Number of
Barrett’s
(%)Variable
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Fig. 2. Cumulative survival of patients with (n=102) and without (n=106) CGA im-
munoreactivity in adenocarcinomas of the GEJ (p=0.69). Broken line represents CGA-
positive tumors, uninterrupted line represents CGA-negative tumors.
Fig. 3. Cumulative survival of patients with (n=38) and without (n=18) CGA immunoreactiv-
ity in Barrett’s mucosa adjacent to adenocarcinoma (p=0.0015). Broken line represents CGA-
positive Barrett’s mucosas, uninterrupted line represents CGA-negative Barrett’s mucosas.
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is an independent predictor of improved survival af-
ter surgery for GEJ adenocarcinomas. To our
knowledge this is the first example that in the con-
current presence of a premalignant lesion and a car-
cinoma a characteristic of the premalignant lesion
has prognostic significance. An explanation for this
finding remains obscure. 
The presence of NE cells in Barrett’s epithelium
has been described by several authors [30–34], sug-
gesting that it arises from a multipotent gastroin-
testinal stem cell probably responsible for the risk of
adenocarcinoma [31,34]. Smith and Haggitt [14]
have provided 4 explanations for the presence of NE
cells in noncarcinoid adenocarcinomas of the gas-
trointestinal tract: (1) entrapment of normal NE
cells within the malignant tumor; (2) benign prolif-
eration of NE cells within a malignant population of
intestinal cells; (3) malignant transformation of 2
distinct stem cell lines (1 neuroendocrine and 1 en-
dodermal); and (4) malignant transformation of 1
stem cell line capable of both endodermal and neu-
roendocrine differentiation. The last hypothesis has
found support from several studies [20,35], includ-
ing that by De Bruïne et al. [36], who demonstrated
mucin and CGA expression in the colorectal cell line
H716. 
Since NE cells comprise an integral part of the in-
testinal epithelium, the presence of NE cells in Bar-
rett’s mucosa can be the mere result of the intesti-
nal-type differentiation. However, additional factors
in NE differentiation can be involved. Duodenogas-
troesophageal reflux is known to be a risk factor for
the development of Barrett’s mucosa. Reflux dis-
ease is often treated by acid-suppressive therapy.
Sanduleanu et al. [37] found that serum CGA in-
creases during profound gastric acid inhibition. Fur-
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Table 3. Results of the Cox Regression Analyses in (A) 208 GEJ Adenocarcinomas and in 
(B) 56 Barrett’s Mucosas (Adjacent to Tumor), as Part of the Series of 208 GEJ Adenocarcinomas
A.
Confounding Variable Univariate RR* (CI†) p Value Multivariate-Adjusted RR‡ (CI) p Value
Age 1.01 (1.0-1.03) 0.15 1.02 (1.0-1.04) 0.11
Gender (M, F) 0.94 (0.59-1.52) 0.81 0.75 (0.45-1.25) 0.27
pTNM—stage: I — <0.001 — 0.003
pTNM—stage: II 3.76 (1.16-12.22) — 2.88 (0.88-9.48) —
pTNM—stage: III 8.43 (2.63-27.04) — 5.35 (1.63-17.56) —
pTNM—stage: IV 8.08 (2.38-27.40) — 5.22 (1.50-18.20) —
Tumor grade: Well — 0.012 — 0.118
Tumor grade: Moderate 6.84 (0.94-49.51) — 4.95 (0.68-36.04) —
Tumor grade: Poor 9.98 (1.38-71.98) — 6.24 (0.85-45.68) —
Radicality of resection 
(R0 vs R1, R2) 2.43 (1.69-3.49) <0.001 1.73 (1.17-2.57) 0.006
CGA tumor 
(positive vs negative) 1.09 (0.77-1.55) 0.63 1.12 (0.78-1.61) 0.56
B.
Age 1.04 (1.0-1.08) 0.035 1.04 (1.0-1.10) 0.030
pTNM-stage
(I, II vs III, IV) 1.92 (0.91-4.03) 0.086 0.63 (0.22-1.83) 0.395
Tumor grade
(well, moderate vs poor) 1.33 (0.65-2.71) 0.435 0.93 (0.35-2.45) 0.883
Radicality of resection 
(R0 vs R1, R2) 2.63 (1.28-5.40) 0.008 2.91 (1.07-7.95) 0.037
CGA Barrett mucosa 
(positive vs negative) 3.12 (1.48-6.58) 0.003 4.21 (1.61-11.0) 0.003
*Relative Risk; †95% Confidence Interval. ‡In multivariate analysis, correction was carried out for the confounding variables age, gen-
der, pTNM stage, tumor grade, radicality of resection, and CGA immunoreactivity in the tumors (A), age, pTNM stage, tumor grade, rad-
icality of resection, and CGA immunoreactivity in Barrett’s mucosa (B), variables are mentioned in the column “Confounding Variables”.
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thermore, Helicobacter pylori infection was associated
with higher serum CGA levels [37]. It should there-
fore be addressed that both long-term acid-suppres-
sive therapy and Helicobacter pylori status might play
a role in CGA expression in Barrett’s mucosa and
adenocarcinomas of the GEJ. Unfortunately, we
were not able to obtain reliable information on pre-
vious acid-suppressive therapy or Helicobacter pylori
status in our patient population. 
Colombo et al. [38] investigated the effect of CGA
on neoplastic growth and morphogenesis by use of
mouse models. They found slower progression of
mouse mammary adenocarcinoma after transfec-
tion of CGA cDNA and suggested that CGA may
contribute to regulate tumor growth in a negative
manner. Given the fact that distal esophageal ade-
nocarcinomas often develop from a precursor le-
sion, i.e., Barrett’s mucosa, being present for years
already before tumor formation, we were able to in-
vestigate the significance of CGA on tumor growth
in 56 patients with Barrett available adjacent to tu-
mor [39]. CGA expression in these Barrett’s mu-
cosas indeed correlated with less advanced pTNM
stage and tumor grade of adjacent tumors as com-
pared to Barrett-related carcinomas without CGA in
the precursor lesion. Furthermore, CGA expression
in the Barrett’s mucosa came forward as an inde-
pendent predictor of survival in Cox regression
analysis. Future experiments focusing on transfec-
tion of CGA cDNA in Barrett’s metaplasia cell lines
could possibly gain more insight in the role of CGA
in GEJ adenocarcinoma development. 
In summary, the current study demonstrates NE
differentiation in Barrett’s epithelium to be corre-
lated with survival in patients with Barrett’s-associ-
ated adenocarcinomas of the GEJ. CGA immunore-
activity in Barrett’s mucosa adjacent to tumor is an
independent prognostic factor for better survival af-
ter surgery. It appears from these data, obtained in a
large patient group, that CGA expression in Bar-
rett’s mucosa might be helpful in the prognostic as-
sessment of patient outcome.
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